Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

Author： Vaddi Kris   Sarlis Nicholas J   Gupta Vikas  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.16, 2012-11, pp. : 2397-2407

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

By  

Current Medicinal Chemistry, Vol. 19, Iss. 26, 2012-09 ,pp. : 4399-4413

Bentham Science Publishers

Access to resources Recommend Favorite

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 10, 2012-10 ,pp. : 1233-1249

Informa Healthcare

Access to resources Recommend Favorite

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 357-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib: JAK2V617F proliferation leading to myelofibrosis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1151, 2007-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Comparison of JAK2V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 269-275

John Wiley & Sons Inc

Access to resources Recommend Favorite